Drug Search Results
More Filters [+]

Sumanirole

Alternative Names: sumanirole
Latest Update: 2023-05-26
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: D2 Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Sumanirole

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Parkinson's Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

M27600011

P3

Terminated

Parkinson's Disease

None

DA2APD-0075-031

P3

Completed

Parkinson's Disease

None

666E-CNS-0075-021

P3

Completed

Parkinson's Disease

None

Recent News Events